Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Zentalis Pharmaceuticals, Inc.

ZNTL ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$1.68

▼ -11.11%

Market Cap $165.09M · Vol 394.66K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$165.09M

Micro Cap

Div Yield

N/A

EPS Growth

+3.06%

YoY

RSI (14)

24.76

Momentum

Beta

1.94

vs Market

52W High

$6.94

75.79% below

52W Low

$1.28

31.25% above

Volume

394.66K

Avg 357.65K

P/B

0.43

Price-to-book

ROE

-49.53%

Return on equity

Free Float

75.34%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Zentalis Pharmaceuticals, Inc. (ZNTL) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ZNTL pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-1.75%

-33.33%

-60.84%

-60.75%

YTD

+24.44%

+25.37%

-83.63%

-97.83%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-137,060,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-49.53%
ROA · ROIC	-37.99% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	0.43
P/FCF	N/A
EPS Growth	+3.06%
Outstanding Shares	98.27M

Technical Indicators

50-Day SMA	$2.58
200-Day SMA	$3.40
RSI (14)	24.76
Beta	1.94
52-Week High	$6.94
52-Week Low	$1.28

Volume Today	394.66K
Avg Daily Volume (30D)	357.65K
Relative Volume	1.10x
Volatility (10D)	71.96
Volatility (30D)	75.51
Free Float	75.34%

Analyst Consensus

BUY

Current Price $1.68

Mean Target $7.44

52W Low$1.28 52W High$6.94

Current

Target

$1.28 $6.94

Current Analyst target

+343.12% upside potential · 11 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG00R2K8TG4

ISINUS98943L1070

CountryUSA

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co., Ltd. -4.87% ARGX.BR argenx SE +1.28% ARGX argenx SE +0.38% GMAB.CO Genmab A/S -0.87% GMAB Genmab A/S -3.95%

Company Profile

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company is engaged in developing azenosertib (ZN-c3), a potentially first-in-class WEE1 inhibitor, for patients with ovarian cancer and other tumor types. The inhibition of WEE1, a DNA damage response kinase, drives cancer cells into mitosis without being able to repair damaged DNA, resulting in cell death and thereby preventing tumor growth and potentially causing tumor regression. WEE1 acts as a regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. In clinical trials, azenosertib has been well tolerated and has demonstrated anti-tumor activity as a single agent across multiple tumor types.